Lidia Pieri
Lidia Pieri is a biotech founder and company builder with a PhD in physics and an Executive MBA in business innovation. She has co-founded and scaled an innovative drug discovery company by integrating deep science, data/AI and disciplined execution.
As the co-founder and CEO of Sibylla Biotech, Lidia has transformed an idea into a multi-programme pipeline, secured over €25 million in funding (seed and Series A) and forged strategic partnerships with global pharmaceutical companies such as Takeda and Ono. She has overseen all aspects of operations, including P&L management, team leadership and governance.
Lidia is passionate about building high-performance teams, establishing credibility with investors and partners, and translating complex scientific concepts into tangible products and value. As a board member of the Italian Tech Alliance, she contributes to national advocacy and technology transfer initiatives aimed at accelerating the commercialisation of public research and strengthening the innovation ecosystem.
ArticleProtein folding interference: a new path to hard-to-drug targets
Protein folding interference offers access to targets long considered unreachable by traditional drug discovery. By acting on transient folding intermediates, this approach presents a new opportunity to eliminate disease-driving proteins.
ArticleWomen in Stem with Lidia Pieri
Lidia Pieri earned a Master’s degree with honours in high energy physics at CERN, a PhD in theoretical astroparticle physics from Rome-3 (Italy) and an Executive MBA in Business Innovation with honours from the MIB school in Trieste. During the academic period she gained international exposure and recognition working as ...